Evidence map›Paper›PMID 25299057›Full record

ArticlePLoS neglected tropical diseases2014

No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in mwea, central kenya, a heavy transmission area.

Agola E Lelo, David N Mburu, Gabriel N Magoma, Ben N Mungai, Jimmy H Kihara, Ibrahim N Mwangi, Geoffrey M Maina, Joseph M Kinuthia, Martin W Mutuku, Eric S Loker and 2 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. The Life Histories of Intermediate Hosts and Parasites ofInternational journal of environmental research and public health · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Mass Drug Administration of Triclabendazole forThe American journal of tropical medicine and hygiene · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Agola E LeloCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
David N MburuKenyatta University, Department of Biochemistry, Nairobi, Kenya.
Gabriel N MagomaDepartment of Biochemistry, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya.
Ben N MungaiCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Jimmy H KiharaCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Ibrahim N MwangiCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Geoffrey M MainaCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Joseph M KinuthiaCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Martin W MutukuCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Eric S LokerDepartment of Biology, University of New Mexico, Albuquerque, New Mexico, United States of America.
Gerald M MkojiCentre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Michelle L SteinauerDepartment of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific Northwest, Western University of Health Sciences, Lebanon, Oregon, United States of America.

Funding

UNM COBRE: THEORETICAL STUDY OF SPECIFICITY OF RNA SILENCING MECHANISMP20RR018754 · NCRR · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2003 to 2011
$16.7M
Snail-Related Studies of Transmission and Control of Schistosomiasis in KenyaR01AI101438 · NIAID · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2012 to 2016
$1.7M
Evo-epidemiology of Scistosoma mansoni in children in KenyaR03TW008127 · FIC · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2008 to 2010
$110k
FIC NIH HHS R01 TW008127FIC NIH HHS R03 TW008127NCRR NIH HHS P20 RR018754NCRR NIH HHS P20RR18754NIAID NIH HHS R01 AI101438
6 · The paper itself

Abstract

backgroundSchistosomiasis is a debilitating neglected tropical disease that infects over 200 million people worldwide. To combat this disease, in 2012, the World Health Organization announced a goal of reducing and eliminating transmission of schistosomes. Current control focuses primarily on mass drug administration (MDA). Therefore, we monitored transmission of Schistosoma mansoni via fecal egg counts and genetic markers in a typical school based MDA setting to ascertain the actual impacts of MDA on the targeted schistosome population.

methodsFor 4 years, we followed 67 children enrolled in a MDA program in Kenya. Infection status and egg counts were measured each year prior to treatment. For 15 of these children, for which there was no evidence of acquired resistance, meaning they became re-infected following each treatment, we collected microsatellite genotype data from schistosomes passed in fecal samples as a representation of the force of transmission between drug treatments. We genotyped a total of 4938 parasites from these children, with an average of 329.2 parasites per child for the entire study, and an average of 82.3 parasites per child per annual examination. We compared prevalence, egg counts, and genetic measures including allelic richness, gene diversity (expected heterozygosity), adult worm burdens and effective number of breeders among time points to search for evidence for a change in transmission or schistosome populations during the MDA program.

findingsWe found no evidence of reduced transmission or schistosome population decline over the course of the program. Although prevalence declined in the 67 children as it did in the overall program, reinfection rates were high, and for the 15 children studied in detail, schistosome egg counts and estimated adult worm burdens did not decline between years 1 and 4, and genetic diversity increased over the course of drug treatment.

interpretationSchool based control programs undoubtedly improve the health of individuals; however, our data show that in an endemic area, such a program has had no obvious effect on reducing transmission or of significantly impacting the schistosome population as sampled by the children we studied in depth. Results like these, in combination with other sources of information, suggest more integrated approaches for interrupting transmission and significantly diminishing schistosome populations will be required to achieve sustainable control.

Indexed as

AdultAnimalsChildCost of IllnessFecesFemaleGenetic VariationGenotypeHumansKenyaMalePrevalenceSchistosoma mansoniSchistosomiasis mansoniSchools

Identifiers

PMID25299057
PMCPMC4191953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.